Objective: To investigate the expression of 11b-hydroxysteroid dehydrogenase (11b-HSD) type 1 and 2 and hexose-6-phosphate dehydrogenase (H6PDH) mRNA in subcutaneous abdominal tissue from lean and obese women with and without polycystic ovary syndrome (PCOS), and to investigate the association between these enzymes and different measures of insulin sensitivity. Design: Cross-sectional study. Subjects: A total of 60 women, 36 women with PCOS, 17 lean (lean PCOS, LP) and 19 obese (obese PCOS, OP) and 24 age-and weight-matched control women, 8 lean (lean controls, LC) and 16 obese (obese controls, OC). Subcutaneous adipose tissue was collected from the abdomen. Peripheral insulin sensitivity was assessed by the euglycemic hyperinsulinemic clamp and determined as glucose disposal rate and insulin sensitivity index. Whole-body insulin sensitivity was calculated using homeostasis model assessment insulin resistance index. Body composition was evaluated by dual X-ray absorptiometry. Adipose mRNA expression of leptin and adiponectin were determined by real-time PCR. Results: Polycystic ovary syndrome (Po0.05) and obesity (Po0.05) were independently associated with increased expression of 11b-HSD1 mRNA. The subgroups LP and OC had increased 11b-HSD1 and 11b-HSD2 mRNA expression compared with LC (Po0.05, Po0.05). There were no effects of PCOS or obesity on11b-HSD2 or H6PDH mRNA expression. Decreased peripheral insulin sensitivity (Po0.001) and increased upper body fat distribution (Po0.01) were associated with increased expression of 11b-HSD1, but neither 11b-HSD2 nor H6PDH. Conclusion: Polycystic ovary syndrome and obesity are independently associated with increased expression of 11b-HSD1. This may lead to increased conversion of cortisone to cortisol in the peripheral adipose tissue and subsequently increased glucocorticoid activity. Decreased peripheral insulin sensitivity and central obesity was associated with increased expression of 11b-HSD1.
Introduction
There is considerable evidence that glucocorticoids have a role in the pathogenesis of obesity and insulin resistance. [1] [2] [3] Both obesity and insulin resistance are contained in the metabolic syndrome characterized by central obesity, dyslipidemia, hyperglycemia and hypertension. Several features of the metabolic syndrome resemble those of Cushing's syndrome, and this similarity has focused interest on the role of glucocorticoids in mediating visceral obesity. Circulating levels of cortisol are neither elevated in obesity nor in insulin resistance. [4] [5] [6] However, circulating levels of cortisol do not reflect tissue concentrations of cortisol in target tissues, such as the liver, adipose tissue and skeletal muscle. The tissue concentration of cortisol is regulated by two isoenzymes of 11b-hydroxysteroid dehydrogenase, 11b-hydroxysteroid dehydrogenase type 1 and 2, (11b-HSD1 and 11b-HSD2). 11b-HSD1 is a bidirectional enzyme, capable of catalyzing both the oxo-reductase (cortisone to cortisol) and dehydrogenase (cortisol to cortisone) reactions. It is widely expressed and highly in the liver and adipose tissue. Studies on 11b-HSD1 in transgenic mice show that overexpression of 11b-HSD1 in adipose tissue results in insulin resistance, 7 whereas 11b-HSD1 knockout mice 8 resist diet-induced insulin resistance compared with wild-type mice, suggesting a possible causative role of 11b-HSD1 in the development of insulin resistance. In humans, increased mRNA levels and activity of 11b-HSD1 have been found in adipose tissue in obesity. 9 Moreover, adipose 11b-HSD1 has been positively associated with insulin resistance independently of obesity in most studies, 5, 10, 11 and inhibition of 11b-HSD seems to protect against development of obesity and enhances insulin sensitivity. 12 11b-HSD1 is strongly dependent on the provision of cofactor nicotinamide adenine dinucleotide phosphate generated by the enzyme hexose-6-phosphate dehydrogenase (H6PDH) in order to function as an oxoreductase. 13, 14 11b-hydroxysteroid dehydrogenase type 2 is expressed in mineralocorticoid target tissues, 15 where its main role is to inactivate cortisol to cortisone thereby protecting the mineralocorticoid receptor from cortisol. Only a limited number of studies have investigated the role of 11b-HSD2, but in a recent study, adipose 11b-HSD2 was found to be positively associated with different measures of obesity and insulin resistance in male Wistar rats, 16 however, the significance of adipose 11b-HSD2 in humans remains unresolved. Polycystic ovary syndrome (PCOS) is characterized by chronic anovulation, hyperandrogenism and polycystic ovaries. The diagnostic criteria for PCOS have been subject of much debate. 17 In this study we have chosen to use the Rotterdam criteria. 18 Although not included in the diagnostic criteria of PCOS, insulin resistance is considered the main pathophysiological mechanism behind the development of the hormonal disturbances associated with PCOS. With clinical and paraclinical characteristics as central obesity, dyslipidemia, glucose intolerance and insulin resistance, PCOS is closely associated with the metabolic syndrome, and women with PCOS are considered at increased risk of type 2 diabetes and cardiovascular disease. Glucocorticoid metabolism in PCOS has been sparsely investigated, but it has been suggested that defective 11b-HSD1 activity may contribute to the development of PCOS. A recent demonstration of a polymorphism in the HSD11B1 gene, which encodes 11b-HSD1, has lead to the suggestion that a genetic variation in the 11b-HSD1 contributes to enhanced cortisol clearance in women with PCOS. 19 Little is known about the regulation of 11b-HSD1 activity. In rodents, the hepatic activity of 11b-HSD1 shows sexual dimorphism with lower activity in females (Low et al. 20 ) , and recently Paulsen et al.
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described lower expression of 11b-HSD1 in lean females compared with lean males. This gender-specific difference in 11b-HSD1 expression may be explained by the difference in sex steroids between males and females. The purpose of this study was to investigate the role of PCOS and obesity on 11b-HSD1, 11b-HSD2 and H6PDH mRNA expression in abdominal subcutaneous adipose tissue. Furthermore, we aimed to investigate the correlation between enzyme mRNA expression and different measures of insulin sensitivity. Oral glucose tolerance test and euglycemic hyperinsulinemic clamp An oral glucose tolerance test, an euglycemic hyperinsuliemic clamp and dual X-ray absorptiometry scan were performed as previously described.
Materials and methods
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Subcutaneaus fat biopsy A subcutaneous fat biopsy was obtained under local anesthesia using a Bergström needle from the lower abdomen in the fasting state. The specimen was immediately dissected free of connective tissue and blood, frozen in liquid nitrogen and stored at À80 1C until assayed.
Laboratory analysis
Plasma glucose was measured by 'Beckman Glucose analyzer' (Ramcon, Fullerton, CA, USA). Testosterone and dihydro-PCOS and 11b-hydroxysteroid dehydrogenase PF Svendsen et al testosterone were measured by radioimmunoassay after ether extraction and subsequent celite chromatography. The intraand inter-assay variations for testosterone were 8.2 and 13.8%, and for dihydrotestosterone 9.1 and 11.0%. The detection limit for both analyses was 0.05 nmol l
À1
. Plasma concentration of sexual hormone-binding globulin (SHBG) was analyzed by a double monoclonal immunofluorometric assay (AutoDelfia, Wallac Oy, Turku, Finland). Intra-and inter-assay variation was 5.2 and 7.5%. Free testosterone was estimated from measurement of SHBG, total testosterone and dihydrotestosterone using the law of mass action, including a calculation of testosterone binding to albumin. 24 Insulin was analyzed by 1235 Auto DELPHIA automatic Immunoassay system (Wallac Oy), with a detection limit of 3 pmol l
.
Isolation of RNA Total RNA was isolated from the biopsies using the TriZol reagent (Gibco BRL, Life Technologies, Roskilde, Denmark); RNA was quantified by measuring absorbency at 260 and 280 nm and the ratio should be X1.8. Finally, the integrity of the RNA was checked by visual inspection of the two ribosomal RNA's 18S and 28S on an agarose gel.
Real-time reverse transcriptase-PCR measurement of 11b-HSD1, 11b-HSD2 and H6PDH mRNA For real-time reverse transcriptase-PCR, cDNA was constructed using random hexamer primers as described by the manufacturer (GeneAmpRNAPCR Kit from Perkin-Elmer Cetus, Norwalk, CT, USA). PCR-mastermix, containing the specific primers, Hot star taq DNA polymerase and SYBR Green PCR buffer was then added. The following primer pairs were used:
Real-time quantification of genes was performed with SYBR Green real-time reverse transcriptase-PCR assay (Qiagen, Inc., Valencia, CA, USA) using an ICycler (Bio-Rad Laboratories, Hercules, CA, USA). Gene mRNA was amplified in separate tubes, and the increase in fluorescence was measured in real time. The threshold cycle (Ct) was calculated, and the relative gene expression was calculated essentially as described in the User Bulletin no. 2, 1997, from Perkin-Elmer. All samples were amplified in duplicate.
A similar setup was used for negative controls except that the reverse transcriptase was omitted and no PCR products were detected under these conditions.
Calculations
Glucose disposal rate (GDR) was determined during the steady-state period of the clamp, and calculated as mg per kg fat-free mass (FFM) per minute. The insulin sensitivity index (ISI) was calculated as: (GDR)/(plasma insulin during last 30 min of clamp), expressed in the units: (mg glucose per kg FFM per min)/(pmol per l insulin). Homeostasis model assessment insulin resistance index (HOMA-IR) was used for the evaluation of whole-body insulin sensitivity. HOMA-IR values were calculated using the 'HOMA Calculator, version 2,2' software (Diabetes Trials Unit, University of Oxford). The software was downloaded from http:// www.dtu.ox.ac.uk/homa. Trunk to peripheral fat ratio was calculated from the whole-body dual X-ray absorptiometry scan as (trunk fat/(arm fat þ leg fat þ head fat).
Statistics
A two-way analysis of variance was used to evaluate the independent effect of PCOS and obesity, respectively on the different variables. Subgroup analyses, using Students t-test and Mann-Whitney test, were carried out comparing lean and obese women with PCOS with their BMI-matched control groups, and comparing obese women with and without PCOS with their lean counterparts. A linear regression analysis was carried out to determine the association between mRNA expression of 11b-HSD1, 11b-HSD2 and H6PDH and different measures of insulin sensitivity. Log transformation was performed on data that did not follow a normal distribution, accounting for 11b-HSD1, 11b-HSD2 and H6PDH. After Log transformation, these data were approximated a normal distribution. Level of significance was set at 0.05.
Results
Women with and without PCOS were compatible regarding age. BMI was similar in obese women with and without PCOS and in lean women with and without PCOS ( Table 1) . PCOS was associated with higher levels of both total (Po0.0001) and free testosterone (Po0.0001) and significantly higher levels of DHAS (Po0.05). Obesity was associated with higher free testosterone levels (Po0.05), higher fasting plasma glucose (Po0.001) and fasting plasma insulin (Po0.0001). Both PCOS and obesity were associated with higher plasma 2-h glucose levels (Po0.05, Po0.0001) and higher trunk/peripheral fat ratios (Po0.001, Po0.0001), (Table 1 ). In the weight-stratified groups, lean women with PCOS had higher levels of both total (Po0.05) and free testosterone (Po0.05), and higher trunk/peripheral fat ratio (Po0.01) than lean control women. Obese women with PCOS and 11b-hydroxysteroid dehydrogenase PF Svendsen et al PCOS also had higher total (Po0.001) and free (Po0.01) testosterone levels and higher DHAS (Po0.05) levels than obese control women. Furthermore obese control women showed higher levels of free testosterone than lean control women (Po0.01). Fasting plasma glucose, 2-h glucose and fasting insulin were higher in obese women with PCOS compared with lean women with PCOS (Po0.05; Po0.01), and in obese control women compared with lean control women (Po0.05; Po0.05). Fasting insulin and trunk/peripheral fat ratio were significantly higher in the two obese groups compared with their respective lean counterparts (Po0.01, fasting insulin; Po0.001, trunk/peripheral fat), (Table 1) .
Insulin sensitivity
Both PCOS and obesity were independently associated with lower insulin sensitivity calculated as either the GDR, (Po0.01, PCOS; Po0.001, obesity) and ISI, (Po0.001, PCOS; Po0.0001, obesity), (Table 2 ). There was a significant negative interaction between PCOS and obesity on ISI, indicating that the presence of both obesity and PCOS has a negative synergistic effect on insulin sensitivity. In the subgroup analysis, we found lower GDR and ISI in lean women with PCOS compared with lean control women (Po0.05, GDR; Po0.01, ISI), in obese women with PCOS compared with lean women with PCOS (Po0.001, GDR; Po0.05, ISI) and in obese control women compared with lean control women (Po0.001, GDR; Po0.001, ISI), (Table 2) . HOMA-IR was significantly higher in the two obese groups compared with their respective lean counterparts (Po0.05).
11b-HSD type 1 and 2 and H6PDH
Both PCOS and obesity were independently associated with higher mRNA expression of 11b-HSD1 in subcutaneous abdominal adipose tissue (Po0.05, PCOS; Po0.01, obesity), (Table 2) . Neither 11b-HSD2 nor H6PDH were affected by the presence of PCOS or obesity (Table 2 ). In the weight-stratified groups, the mRNA expression of 11b-HSD1 and 11b-HSD2 was higher in lean women with PCOS (Po0.05; Po0.05), and in obese compared with lean control women (Po0.05; Po0.05), (Table 2, Figure 1 ). H6PDH did not differ between the groups (Table 2, Figure 1 ). There was a significant positive association between 11b-HSD1 and trunk/peripheral fat (Po0.01) and a significant negative association between 11b-HSD1 and both GDR (Po0.01) and ISI (Po0.001), (Table 3 ). There was a borderline significant positive correlation between 11b-HSD1 and HOMA (P ¼ 0.06), (Table 3) . We found no association between 11b-HSD2 and H6PDH and the different measures of insulin sensitivity (Table 3) .
Discussion
The role of the adrenals and cortisol metabolism in the etiology of PCOS has long been debated. Enhanced Po0.0001
Po0.05
Po0.001 PCOS and 11b-hydroxysteroid dehydrogenase PF Svendsen et al 5a-reductase activity, dysregulation of 11b-HSD1 activity and increased adrenal steroid production rates have previously been described in PCOS. [25] [26] [27] [28] It is well known that PCOS can be associated with increased DHAS, [29] [30] [31] [32] [33] which is confirmed here, indicating increased cortical activity. In this study, we have also investigated the mRNA expression of 11b-HSD1, 11b-HSD2 and H6PDH in subcutaneous adipose tissue biopsies from lean and obese women with or without PCOS. In order to avoid obesity-related effects on cortisol metabolism, we carried out a two-way analysis of variance, which allows assessment of the independent effect of PCOS and obesity on the relevant variables. In our study, both PCOS and obesity was independently associated with higher expression of adipose11b-HSD1 mRNA, indicating increased oxo-reductase activity leading to increased reactivation of cortisol from cortisone. There seems to be some scientific controversies regarding cortisol metabolism in PCOS. In a previous study, Gambineri et al. 19 investigated a functional polymorphism in the HSD11B1 gene, associated with lower 11b-HSD1 activity, in women with and without PCOS. They found that this polymorphy was associated with the PCOS status, and they suggested that the enhanced cortisol clearance caused by this polymorphy would lead to increased adrenocorticotropic hormone and subsequently increased release of adrenal androgens. However, only the lean phenotype of PCOS was investigated in order to avoid the confounding effect of obesity on glucocorticoid metabolism. In contrast, a recent study found that adipose 11b-HSD1 was increased in women suffering from PCOS compared with healthy controls. 34 Two other studies have failed to show any polymorphisms in the HSD11B1 gene, and our results do not indicate reduced adipose cortisol production. 35, 36 These results are not in line with our findings, possibly because of differences in study populations and methodology.
In human adipose tissue, the majority of studies suggest a positive association between 11b-HSD1 gene expression and activity and obesity, 6,9,10,37-39 whereas hepatic 11b-HSD1 seems to be decreased in obesity. 4, 6, 9 Similarly, we found a positive association between obesity and tissue levels of 11b-HSD1 mRNA. We furthermore found a significant positive correlation between the expression of 11b-HSD1 mRNA and trunk/peripheral fat, suggesting that adipose 11b-HSD1 is more closely associated with central obesity than obesity per se. This finding corresponds well with findings in transgenic mice overexpressing 11b-HSD1 in adipose tissue as they predominantly accumulate visceral fat. 7 We found a significant negative correlation between the expression of 11b-HSD1 mRNA and peripheral insulin sensitivity, but only a borderline significant positive correlation between 11b-HSD1 and whole-body insulin sensitivity evaluated by HOMA-IR. In accordance, animal studies have shown increased insulin resistance in transgenic rodents overexpressing 11b-HSD1 in adipose tissue to a level similar to what can be seen in obese individuals. 7 This indicates that increased local production of active cortisol in adipose tissue might cause whole-body insulin resistance. However, as this study is a purely descriptive study, we cannot determine causality, and in fact, it could be speculated that high insulin may somehow influence 11b-HSD1 expression and cortisol metabolism in adipose tissue. In the liver, the expression and activity of 11b-HSD1 is increased in male rats compared with female rats, 40 and estrogen treatment represses hepatic 11b-HSD1 mRNA expression and activity in rodents. 41, 20 Whole-body 11b-reductase activity, which primarily reflects hepatic 11b-HSD1activity, is higher in men than in women, [42] [43] [44] suggesting a genderspecific regulation also in humans. Lean women have lower 11b-HSD1 expression in adipose tissue than lean men; however, this gender-specific difference disappears in obesity. 21 In female rats, ovariectomy results in an increase in adipose 11b-HSD1, but this change may be caused by changes in body composition rather than a direct effect of estrogen deprivation on adipose 11b-HSD1. 45 In contrast, gonadectomy in male rats results in a reduction of both adipose and hepatic 11b-HSD1 activity and mRNA levels, suggesting that androgens may stimulate both hepatic and adipose 11b-HSD1. 46 In line with PCOS and 11b-hydroxysteroid dehydrogenase PF Svendsen et al these results, we found a higher expression of 11b-HSD1 in lean women with PCOS compared with lean control women, which may be explained by significantly higher androgen levels in lean women with PCOS compared with lean control women. This explanation is supported by similar expression of 11b-HSD1 in lean and obese women with PCOS, who have comparable androgen levels. Our study may be underpowered, but the results are in accordance with the study by Paulsen et al. 2007 , finding similar levels of obese men and women in contrast to the differences found in lean men and women. If androgens have a role in the regulation of 11b-HSD1 expression, these regulatory mechanisms seem to be blunted when obesity develops. The pathophysiological mechanisms behind these regulatory processes remain, however, unexplained.
We also investigated the expression of the 11b-HSD2 and H6PDH mRNA, but found no effect of PCOS or obesity on the expression of these enzymes. To our knowledge, adipose 11b-HSD2 and H6PDH have not previously been investigated in PCOS.
Our findings support the theory of an altered glucocorticoid metabolism in PCOS. However, it remains unknown whether these alterations are primary or secondary to the development of PCOS. This is the first study investigating the HSD1, HSD2 and H6PDH gene expression in adipose tissue biopsies from women with and without PCOS. We were able to demonstrate higher 11b-HSD1 mRNA expression in adipose tissue from women with PCOS and in obese women, indicating that an increase in local production of cortisol might have a role in the metabolic disturbances found in these women. In addition, we found a negative association between different measures for insulin sensitivity and adipose tissue 11b-HSD1 expression, which further strengthens our hypothesis that increased 11b-HSD1 expression also in PCOS is associated with insulin resistance as commonly seen in obesity. One of the weaknesses with this study is that we have only determined mRNA expression of HSD1, HSD2 and H6PDH, but not protein and enzyme activities. In previous studies of 11 b-HSD1 in obesity and metabolic syndrome, 11b-HSD1 gene expression correlates strongly with both the 11b-HSD1 activity (measured as the conversion of cortisol to cortisone in tissue homogenates driven by excess cofactors for the 11b-HSD1 dehydrogenase, which corresponds with the amount of 11b-HSD1 enzyme) and with the activity measured as the net production of cortisol from cortisone in cultures adipocytes or tissue samples, which reflects the net 11b-HSD1 reductase activity of the total 11b-HSD system. 37, 21, 45 It would, however, be relevant to perform protein and enzyme determination on this group of patients in future studies. and 2) and hexose-6-phosphate dehydrogenase in lean and obese women with and without polycystic ovary syndrome (PCOS). Median and 25th percentile. LC, lean controls; LP, lean PCOS; OC, obese controls; OP, obese PCOS. *Po0.05 vs lean controls, Mann-Whitney U-test.
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